Año 2026 / Volumen 118 / Número 1
Editorial
Pancreatic neuroendocrine tumors — Bridging knowledge gaps for better outcomes

1-4

DOI: 10.17235/reed.2025.11255/2025

Diana Fresneda Cuesta, José Díaz Tasende,

Resumen
Clinical decision-making in patients with pancreatic neuroendocrine tumors is complex. The absence of effective biomarkers and the reliance on morphological criteria underlying current predictive models expose patients to a substantial risk of overdiagnosis and overtreatment. The implementation of non-invasive tools that improve the precision of prognostic estimates remains an unmet clinical need.
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1 Mohindroo C, Baydogan S, Agarwal P, et al. Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors. Cancer Prev Res (Phila). 2024;17:335-342. doi:10.1158/1940-6207.
2 Yang Z, Shi G. Comparative outcomes of pancreatic neuroendocrine neoplasms: A population-based analysis of the SEER database. Eur J Surg Oncol. 2022;48(10):2181-2187. doi:10.1016/j.ejso.2022.05.016.
3 Rindi G, Klimstra DS, Abedi-Ardekani B, et al: A common classification framework for neuroendocrine neoplasms: An International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018; 31:1770-1786. doi: 10.1038/s41379-018-0110-y.
4 Kos-Kudła B, Castaño JP, Denecke T, et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023;35:e13343. doi: 10.1111/jne.13343.
5 Howe JR, Merchant NB, Conrad C, et al: The North American Neuroendocrine Tumor Society Consensus Paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 49:1-33, 2020.
6 National Comprehensive Cancer Network. Neuroendocrine and Adrenal Tumors (Version 5.2024). https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed February 10, 2025.
(Version 5.2024 ). https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed February 10, 2025.
7 van Beek DJ, Takkenkamp TJ, Wong-Lun-Hing EM, et al. Risk factors for complications after surgery for pancreatic neuroendocrine tumors. Surgery. 2022;172(1):127-136. doi:10.1016/j.surg.2022.02.007.
8 Partelli S, Massironi S, Zerbi A, et al. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial. Br J Surg. 2022;109(12):1186-1190. doi:10.1093/bjs/znac267
9 Tanaka M, Heckler M, Mihaljevic AL, et al. Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2021;28(3):1614-1624. doi:10.1245/s10434-020-08850-7.
10 Assi HA, Mukherjje S, Kunz PL et al: Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database The Oncologist 2020; 25:e276–e283 .
11 Heidsma CM, Tsilimigras DI, Rocha F, et al. Clinical relevance of performing endoscopic ultrasound-guided fine-needle biopsy for pancreatic neuroendocrine tumors less than 2 cm. J Surg Oncol. 2020;122(7):1393-1400. doi:10.1002/jso.26158.
12 Tacelli M, Bina N, Crinò SF, et al. Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data. Gastrointest Endosc. 2022 ;96(6):898-908.e23. doi: 10.1016/j.gie.2022.07.014. Epub 2022 Jul 19. PMID: 35863518.
13 Nguyen M, Li M, Travers A, Segelov E. Role of Chromogranin A in the Diagnosis and Follow-up of Neuroendocrine Tumors: Real-World Experience. Pancreas. 2022;51(8):1007-1010. doi:10.1097/MPA.0000000000002132.
14 Partelli S, Muffatti F, Andreasi V, et al. A Single-center Prospective Observational Study Investigating the Accuracy of Preoperative Diagnostic Procedures in the Assessment of Lymph Node Metastases in Nonfunctioning Pancreatic Neuroendocrine Tumors. Ann Surg. 2022;276(5):921-928. doi:10.1097/SLA.0000000000005615.
15 Heidsma CM, Engelsman AF, van Dieren S, et al. Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA). Br J Surg. 2021;108:888-891. doi: 10.1093/bjs/znab088. PMID: 33783475; PMCID: PMC10364894.
16 Kim JY, Brosnan-Cashman JA, An S, et al. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. Clin Cancer Res. 2017;23(6):1598-1606. doi:10.1158/1078-0432.CCR-16-1147.
17 Öberg K, Califano A, Strosberg JR, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol. 2020;31(2):202-212. doi:10.1016/j.annonc.2019.11.003.
18 Bodei L, Kidd MS, Singh A, et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging. 2020;47(4):895-906. doi:10.1007/s00259-019-04601-3
19 Homps M, Soyer P, Coriat R, et al. A preoperative computed tomography radiomics model to predict disease-free survival in patients with pancreatic neuroendocrine tumors. Eur J Endocrinol. 2023;189(4):476-484. doi:10.1093/ejendo/lvad130.
20 Ma M, Gu W, Liang Y, et al. A novel model for predicting postoperative liver metastasis in R0 resected pancreatic neuroendocrine tumors: integrating computational pathology and deep learning-radiomics. J Transl Med. 2024;22(1):768. Published 2024 Aug 14. doi:10.1186/s12967-024-05449-4.
Artículos relacionados

Carta al Editor

Tumores neuroendocrinos quísticos del páncreas

DOI: 10.17235/reed.2017.5390/2017

Carta al Editor

Tumores neuroendocrinos de páncreas: claves para afrontar la heterogeneidad

DOI: 10.17235/reed.2017.4997/2017

Carta al Editor

Tumores neuroendocrinos pancreáticos

DOI: 10.17235/reed.2017.4725/2016

Instrucciones para citar
Fresneda Cuesta D, Díaz Tasende J. Pancreatic neuroendocrine tumors — Bridging knowledge gaps for better outcomes. 11255/2025


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1287 veces.
Este artículo ha sido descargado 172 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 02/04/2025

Aceptado: 22/04/2025

Prepublicado: 18/12/2025

Publicado: 14/01/2026

Tiempo de prepublicación: 260 días

Tiempo de edición del artículo: 287 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2026 y Creative Commons. Revista Española de Enfermedades Digestivas